Acinetobacter baumannii as a cause of sepsis;Acinetobacter baumannii kao uzročnik sepsi

Medicinski Glasnik

Volumn 9, Issue 2, 2012, Pages 311-316

  Šiširak, Maida ^a   Hukić, Mirsada ^a  

^a University Clinical Centre of Sarajevo   (Bosnia and Herzegovina)

Author keywords

Carbapenems; Nosocomial infections; Resistance

Indexed keywords

AMIKACIN; CARBAPENEM; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; MEROPENEM; TOBRAMYCIN; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; DISK DIFFUSION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MICROBIAL SENSITIVITY TEST; NONHUMAN; SEPSIS; CROSS INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; SEPSIS;

EID: 84868258621     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Garner JS, Jarvis WR, Grace Emori T, Horan TC, Haughes JM. CDC definition for nosocomial infections. Am J Infect Control 1988; 16:128-40.
2. Farr B. Preventing vascular catheter-related infections: current controversies. Clin Infect Dis 2001; 33: 1733-8.
3. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens:microbiological and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
4. Villegas MV, Hartstein AI. Acinetobacter outbreaks 1977-2000. Infect Control Hosp Epidemiol 2003; 24: 284-95.
5. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006; 42:692-99.
6. Gaynes R, Edwards JR. National Nosocomial Infections Surveillance System. Overwiev of infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41: 848-54.
7. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, Rimar D, Almog Y, Gilard J. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003; 54:32-8
8. Mahgoub S, Ahmed J, Glatt AE. Underlying characteristics of patients harboring highly resistant Acinetobacter baumannii. Am J Infect Control 2002; 30:386-90.
9. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krickhali T, Siegman-Igra Y, Carmeli Y. Multdrug-resistant Acinetobacter baumannii. Emerg Infect Dis 2005; 11: 22-9.
10. Wong TH, Tan BH, Ling ML, Song C. Multi-resistant Acinetobacter baumannii on a burns unit-clinical risk factors and prognosis. Burns 2002; 28:349-57.
11. Bush K, Jacoby GA. Updated Functional Classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54:969-76.
12. Afzal MS, Livermore D. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998; 41:576-7.
13. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Boisson C, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994; 32:2677-81.
14. Tenover FC, Arbeit R, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233-9.
15. th ed. (Vol 1). Texas: American Society for Microbiology, 2011.
16. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Fifteenth Informational Supplement. CLSI document M100-S15, Wayne, Pennsylvania, 2005.
17. Ligozzi M, Bernini C, Bonora MG, de Fatima M, Zuliani J, Fontana R. Evaluation of the Vitek 2 system for identification and antimicrobial susceptibility testing of medically relevant Gram-positive coci. J Clin Microbiol 2002; 40:1681-6.
18. Nonhoff C, Rottiers S, Struelens J. Evaluation of the Vitek 2 system for identification and antimicrobial susceptibility testing of Staphylococcus spp. Clin Microbiol Infect 2005; 11: 150-3.
19. Blot S, Vandewoude K, Colardin F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 2003; 29:471-5.
20. Cisneros JM, Reyes MJ, Pachon J. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
21. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued in 1999. Am J Infect Control 1999; 27:520-32.
22. Fridkin SK, Steward CD, Edwards JR. Surveillance of antimicrobial use and antimicrobial resistance in United States hospital: project ICARE phase 2. Clin Infect Dis 1999; 29:245-52.
23. Hsueh PR, Liu YC, Yang D, Yan JJ, Wu TL, Huang WK, Wu JJ, Ko WC, Leu HS, Yu CR, Lun KT. Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan. Microb Drug Resist 2001; 7: 373-82.
24. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka SK, Rahal J. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymixin B and sulbactam. Lancet 1994; 344: 1329-32.
25. Pfaller MA, Jones RN for the MYSTIC Study Group(Americas). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000; 46: 25-37.
26. Wroblewska MM, Towner KJ, Marchel H, Luczak M. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland. Clin Microbiol Infect 2007; 13:490-6.
27. th Congress of Hospital Infection Control in Bosnia and Herzegovina, Tuzla, Bosnia and Herzegovina, 2005. Acta Med Sal 2005; 34 (1): 42.
28. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11(2): 93-100.
29. Deaney NB, Tate H. A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients. J Antimicrob Chemother 1996; 37: 975-86.
30. Rahal J, Urban C, Segal-Maurer S. Nosocomial antibiotic resistance in multiple Gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis 2002; 34: 499-503.
31. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int J Antimicrob Agents 1999; 13: 117-25.
32. Lopez-Hernandez S, Alarcon T, Lopez-Brea M. Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1998; 17:282-5.
33. Da Silva GJ, Leitao J, Peixe L. Emergence of carbapenem-hydrolizing enzymes in Acinetobacter baumannii clinical isolates. J Clin Microbiol 1999; 37:2109-10.
34. Rodriguez-Bano J, Pascual A, Galvez J, et al. Acinetobacter baumannii bacteraemia: clinical and prognostic features. Enferm Infec Microbiol Clin 2003; 21: 242-7.
35. Falagas M, Kasiakou S, Rafailidis P, Zouglakis G and Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57:1251-4.
36. Gur D, Korten V, Unal S, Deshpande L, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58) producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008; 57:1529-32.
37. th Balkan Congress of Microbiology, Belgrade, Serbia, 2011.
38. Berrington A. Hospital antibiotic prescribing data require careful local interpretation. J Antimicrob Chemother 2007; 59: 162-3.
39. Goossens H, Ferech M, Vander Stichele RH, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-87.
40. Perez F, Hujer MA, Hujer MK, Decker KB, Rather NP, Bonomo AR. Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 3471-84.
41. Courvalin P. Antimicrobial drug resistance. Emerg Infect Dis 2005; 11:1503-6.